{"contentid": 488049, "importid": NaN, "name": "Two-year data detail impact of Evrysdi in SMA", "introduction": "Basel\u00e2\u0080\u0099s Roche has announced new exploratory two-year data from the SUNFISH study of Evrysdi (risdiplam) in spinal muscular atrophy (SMA).", "content": "<p>Basel&rsquo;s Roche (ROG: SIX) has announced new exploratory two-year data from the SUNFISH study of Evrysdi (risdiplam) in spinal muscular atrophy (SMA).</p>\n<p>The Swiss cancer giant is testing the SMN2 splicing modifier as an option for people with Type 2 or non-ambulant Type 3 SMA.</p>\n<p>The data suggests that gains in motor function after the first year are sustained for another 12 months, across primary and secondary endpoint measures.</p>\n<p>These results add to recently published data from the FIREFISH trial, which showed that treatment with Evrysdi almost doubled levels of the SMN protein for the high-dose group.</p>\n<p>Details from the SUNFISH study will be presented at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical &amp; Scientific Conference.</p>\n<h2>More choice in SMA</h2>\n<p>Marketed in the USA by Roche subsidiary Genentech, Evrysdi is the first at-home, orally administered treatment for SMA in adults and children over the age of two.</p>\n<p>The treatment, which has been developed in collaboration with PTC Therapeutics (Nasdaq: PTCT) and the SMA Foundation, is expected to provide stiff competition for other options with a less patient-friendly mode of administration.</p>\n<p>Rivals include Biogen&rsquo;s (Nasdaq: BIIB) Spinraza (nusinersen) and Novartis&rsquo; (NOVN: V) Zolgensma (onasemnogene abeparvovec).</p>\n<p>First approved in 2020, the therapy took in 55 million Swiss francs ($59 million) sales last year. Analysts have forecast peak sales potential of up to $2 billion.</p>\n<p>Commenting on the most recent data, principal investigator Eugenio Mercuri said: &ldquo;These results build on the one-year findings from the SUNFISH trial and importantly show the durability of improvement or stabilization of motor function through two years of treatment.&rdquo;</p>\n<p>He added: &ldquo;In addition, with no new safety signals identified, these second year results may support the favorable benefit-risk profile of Evrysdi over a longer period of time.&rdquo;</p>\n<p>At this time, Evrysdi has been approved in seven countries and submitted in 57, including the EU 27 and Norway and Iceland.</p>", "date": "2021-03-16 10:36:00", "meta_title": NaN, "meta_keywords": "Evrysdi, data, two-year, SUNFISH, Roche, study, muscular, treatment, impact, detail, announced, exploratory, risdiplam, spinal, atrophy, Basel\u00e2\u0080\u0099s, results", "meta_description": "Basel\u00e2\u0080\u0099s Roche has announced new exploratory two-year data from the SUNFISH study of Evrysdi (risdiplam) in spinal muscular atrophy (SMA).", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-16 10:21:57", "updated": "2021-03-16 10:38:25", "access": NaN, "url": "https://www.thepharmaletter.com/article/two-year-data-detail-impact-of-evrysdi-in-sma", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "evrysdi_big.jpg", "image2id": "evrysdi_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "CNS Diseases, Musculoskeletal", "topic_tag": "Drug Trial, Research", "geography_tag": "Switzerland, USA", "company_tag": "PTC Therapeutics, Roche", "drug_tag": "Evrysdi", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-16 10:36:00"}